Health · Pharma & Biotech · 22 hrs ago
Verdiva ends mid-stage trial of its GLP-1 obesity pill
Verdiva Bio has ended a mid-stage trial of its obesity drug candidate.
The drug is a GLP-1 pill, a type of treatment being developed for obesity.
Verdiva said it stopped the trial because of changes in the market.
The company is one of several well-funded private biotech firms seeking a place in the obesity drug market.
Ending the trial means this study of Verdiva’s pill will not continue.
No further plans were stated.
Verdiva Bio has ended a mid-stage trial of its GLP-1 obesity pill.
The company cited “market evolution” as the reason, according to the Endpoints News headline.
The article describes Verdiva Bio as a privately held biotech seeking to enter the obesity drug market.
Endpoints News published the article on October 13, 2026.
- Who
- Verdiva Bio.
- What
- It ended a mid-stage trial of its GLP-1 obesity pill.
- When
- The article was published on October 13, 2026; the timing of the trial’s termination is not stated.
- Where
- Not stated.
- Why
- The company cited “market evolution,” according to the article headline.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Verdiva Bio
- Trial stage
- Mid-stage
- Drug type
- GLP-1 obesity pill
- Stated reason
- Market evolution
- Article publication date
- October 13, 2026